Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indian Regulator Tightens Drug Price-Control Loopholes

This article was originally published in PharmAsia News

Executive Summary

India's drug-pricing authority warns pharmaceutical companies they need approval before they can introduce new drugs containing ingredients that are under price controls. The National Pharmaceutical Pricing Authority changed its guidelines to tighten controls on companies using loopholes to avoid price controls. The new guidelines are intended to crack down on repeat offenders, so the second move to avoid price controls is to result in automatic prosecution, instead of waiting for several rounds of hearings and other moves before action is taken. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068831

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel